Nabriva Therapeutics adjourns the Extraordinary General Meeting of Shareholders on December 22, 2021
– Meeting to be reconvened on January 14, 2022 –
DUBLIN, Ireland and FORT WASHINGTON, Pa., December 22, 2021 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its intention to adjourn, without deliberation, its Extraordinary General Meeting of Shareholders (EGM), currently scheduled for Wednesday, December 22, 2021 at 5:00 p.m. Irish time (12:00 p.m. US Eastern Time) to allow the Company to solicit from its shareholders the additional proxies necessary to obtain the approval of the proposal described in the definitive proxy circular of the Company filed with the Securities and Exchange Commission on November 22, 2021 (Proxy). The AGE will meet again on Friday, January 14, 2022, starting at 5:00 p.m. Irish time (12:00 p.m. EST) at 25-28 North Wall Quay, Dublin 1, Ireland.
The EGM registration date continues to be close of business on November 19, 2021. A registered shareholder may use any of the following methods to vote:
Vote over the Internet at www.proxyvote.com until 11:59 p.m. EST on January 13, 2022 using the PIN / other unique identifier shown on the proxy card.
Vote by phone by dialing the toll-free number 1-800-690-6903 until 11:59 p.m. EST on January 13, 2022 using your PIN / other unique identifier appearing on the proxy card.
Vote by mail by filling out, dating and signing the proxy card and returning it in the postage-paid envelope provided with the Statement of proxy.
Vote in person by attending the EGM.
To vote for shares held in the name of the street, holders will need to follow the instructions provided by their brokerage firms.
Proxies previously submitted with respect to the EGM will be voted on at the new EGM, unless they are properly revoked; shareholders who have previously given a proxy or voted in another way and who do not wish to change their vote do not need to take any action. No modification was made to the proposal submitted to the vote of the shareholders at the EGM. The proxy statement is available at https://www.sec.gov/ and at www.proxyvote.com.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics has received US Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic antibiotic based on pleuromutilin for the treatment of community-acquired bacterial pneumonia (CAP). Nabriva Therapeutics is also developing CONTEPO ™ (fosfomycin) for injection, a first-class epoxy antibiotic with potential for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
All statements in this press release regarding the future expectations, plans and prospects of Nabriva Therapeutics, including, but not limited to, statements regarding the date on which the EGM will meet and other statements containing the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “plan”, “target”, ” , ”,“ Continue ”and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors, including: uncertainties regarding the solicitation of proxies and other material factors as set out in Nabriva Therapeuti’s annual and quarterly reports cs and other documents filed with the SEC. In addition, the forward-looking statements included in this press release represent the views of Nabriva Therapeutics as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may change its point of view. However, although Nabriva Therapeutics may choose to update these forward-looking statements at some time in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be taken as representing the views of Nabriva Therapeutics as of a date subsequent to the date of this press release.
Nabriva Therapeutics plc
For the media